Today, the FDA granted a label expansion approval for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody, a companion diagnostic, to identify patients with HR-positive, HER2 ...

ITI Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022 ...

The primary analysis showed a median PFS of 13.2 months with T-DXd and 8.1 months with chemotherapy, representing a 36% reduction in the hazard ratio for disease progression or death (95% CI 0.54 ...

In late 2019, trastuzumab deruxtecan was approved for the treatment of metastatic HER2/neu-positive breast cancer based on a phase two single arm trial that showed an extremely high response rate ...

HER2-positive tumors can also be estrogen-receptor-positive (triple-positive breast cancer). However, ... The mutation causes the gene to produce too many HER2/neu proteins (or just HER2 proteins).

Again, the roughly 15% of cases that overexpress HER2/neu are referred to as HER2/neu-amplified or HER2/neu-positive; this is very relevant for the physician team taking care of the patient with ...

Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based tests to inform decisions about adjuvant chemotherapy for patients with a ...

Her2/neu immunostaining of formalin-fixed tumour tissues. Formalin-fixed, paraffin-embedded tissue blocks from the USC patients from whom primary cell lines were established were retrieved from ...

HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. As both are involved in cell cycle regulation we analyzed whether there was a direct interaction between the two.

RESULTS: HER-2/neu status was available for 651 patients with ER-positive disease; 650, 608, and 353 patients were assessed by IHC, PCR, and FISH, respectively. Approximately one half received ...

Comparison of Chemotherapy With Chemohormonal Therapy as First-Line Therapy for Metastatic, Hormone-Sensitive Breast Cancer: An Eastern Cooperative Oncology Group Study PURPOSE: The purpose of this ...